Article Information
History
- April 6, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Anastasia S. Lambrou1,2,*,
- John T. Redd1,
- Miles A. Stewart1,2,
- Kaitlin Rainwater-Lovett1,2,
- Jonathan K. Thornhill1,2,
- Lynn Hayes1,
- Gina Smith1,
- George M. Thorp1,
- Christian Tomaszewski3,4,
- Adolphe Edward3,4,
- Natalia Elías Calles5,
- Mark Amox6,
- Steven Merta6,
- Tiffany Pfundt1,
- Victoria Callahan1,
- Adam Tewell1,
- Helga Scharf-Bell1,
- Samuel Imbriale1,
- Jeffrey D. Freeman1,2,
- Michael Anderson1 and
- Robert P. Kadlec1
- 1Office of the Assistant Secretary for Preparedness and Response, U. S. Department of Health and Human Services, Washington, DC, U.S.
- 2Johns Hopkins University Applied Physics Laboratory, Laurel, Maryland, U.S.
- 3El Centro Regional Medical Center, El Centro, CA, U.S.
- 4UC San Diego Health, San Diego, CA, U.S.
- 5TMC HealthCare, Tucson, AZ, U.S.
- 6Sunrise Hospital and Medical Center, Las Vegas, NV, U.S.
- ↵*CORRESPONDING AUTHOR
Anastasia S. Lambrou, PhD, Anastasia.Lambrou{at}hhs.gov
Posted April 06, 2021.
Implementation of SARS-CoV-2 monoclonal antibody infusion sites at three medical centers in the United States: Strengths and challenges assessment to inform COVID-19 pandemic and future public health emergency use
